rs10033900 — CFI

CFI rs10033900 — The Complement Regulator and Retinal Aging

Your complement system is a rapid-response arm of innate immunity that can neutralize pathogens and clear cellular debris within seconds. But like any powerful defense, it requires constant regulation to avoid harming healthy tissue. Complement factor I (CFI)¹¹ Complement factor I (CFI)
A serine protease enzyme that inactivates C3b and C4b, preventing runaway complement activation is one of the key brakes on this system — a circulating protease that cleaves and permanently inactivates the activated complement fragments C3b and C4b, preventing complement amplification²² complement amplification
The cascade-like process where each activated complement protein rapidly activates many more, exponentially amplifying the immune response from spiraling out of control.

rs10033900 is an intronic variant within the CFI gene on chromosome 4. While it doesn't alter the CFI protein sequence directly, it influences CFI expression or function in a way that is robustly associated with age-related macular degeneration (AMD)³³ age-related macular degeneration (AMD)
Progressive degeneration of the macula (central retina), the leading cause of vision loss in people over 60 risk across multiple populations. The T allele (carried by roughly 46% of people globally) is associated with reduced complement regulation in the subretinal space, predisposing to the chronic low-grade inflammation that drives drusen formation, retinal pigment epithelium damage, and ultimately the geographic atrophy or choroidal neovascularization that defines advanced AMD.

The Mechanism

CFI cleaves C3b in partnership with cofactor proteins⁴⁴ cofactor proteins
Proteins that present C3b to CFI for cleavage, including CFH (complement factor H), MCP, and CR1 — most importantly complement factor H (CFH). In the subretinal space and Bruch's membrane⁵⁵ Bruch's membrane
A thin layer between the retinal pigment epithelium and the choroidal blood supply, where drusen deposits accumulate in AMD, CFI activity is critical for preventing C3b from accumulating and driving continuous complement activation. The CFI gene has rare loss-of-function mutations that cause complete complement factor I deficiency (a severe immunodeficiency), but the common rs10033900 variant exerts a milder, quantitative effect on complement regulation.

How exactly rs10033900 alters CFI function remains under investigation — it may affect transcriptional regulation, mRNA splicing efficiency, or regulatory element binding within intron 10 of the CFI gene. What is clear from functional data is that the T allele is associated with subtly reduced complement regulatory capacity in the retinal microenvironment. This allows C5b-9⁶⁶ C5b-9
The membrane attack complex, the terminal complement complex that creates pores in cell membranes assembly and pro-inflammatory cytokine release to proceed at elevated levels, contributing over decades to the chronic subretinal inflammation that characterizes AMD pathogenesis.

The drusen that form in AMD — lipid-protein deposits beneath the retinal pigment epithelium — are rich in complement components including C3, C5, and the membrane attack complex, providing direct histological evidence for complement dysregulation as a central mechanism. The CFI locus sits within a broader complement genetics story for AMD that also includes CFH Y402H⁷⁷ CFH Y402H
The strongest single genetic risk factor for AMD, affecting complement factor H's ability to protect Bruch's membrane from complement attack and CFB/C2 variants⁸⁸ CFB/C2 variants
Complement component genes on chromosome 6, where protective haplotypes reduce AMD risk by 40-50%. CFI contributes an independent signal at this locus.

The Evidence

The evidence for rs10033900 has accumulated across multiple ethnicities and AMD subtypes, though effect sizes are moderate and some studies in small or ethnically distinct cohorts have not replicated the finding.

A 2020 meta-analysis⁹⁹ 2020 meta-analysis
Comprehensive pooling of 12 case-control studies by Yu et al. found a statistically significant protective association between the C allele and AMD risk in the overall pooled analysis and in Caucasian populations specifically, with consistent protection observed across both neovascular AMD and geographic atrophy subtypes. The analysis covered studies genotyping 12 case-control cohorts and applied subgroup analyses by ethnicity and AMD subtype.

Direct effect sizes appear in a Chinese case-control study¹⁰¹⁰ Chinese case-control study
379 participants (119 exudative AMD, 120 early AMD, 140 controls) at a tertiary eye center by Wu et al. (2013): the minor C allele frequency was 17.4% in exudative AMD patients versus 29.3% in controls, yielding an odds ratio of 0.57 (95% CI 0.36–0.88, P=0.002) — a 43% reduction in exudative AMD risk per C allele. The C allele showed a similar protective trend for early AMD but did not reach significance in that subgroup.

Disease progression data comes from a Dutch longitudinal cohort¹¹¹¹ Dutch longitudinal cohort
278 AMD patients followed for second-eye progression by Lechanteur et al. (2012): TT homozygotes (homozygous risk genotype) showed a hazard ratio of 2.2 (95% CI 1.1–4.3) for accelerated progression to end-stage AMD in the second eye compared to CC individuals, establishing that the genotype influences not just AMD incidence but also the speed of disease advance once it begins.

The CFI locus was also validated in a large GWAS¹²¹² large GWAS
2,157 AMD cases and 1,150 controls by Chen et al. (2010, PNAS) that confirmed the CFI association alongside TIMP3, LIPC, and CETP loci, with P < 10⁻⁶ — meeting genome-wide significance thresholds.

Some studies, particularly in Turkish (Bezci Aygun et al., 2020) and Algerian (Abid et al., 2022) populations, have not found significant associations with rs10033900, likely reflecting the smaller sample sizes (n=111 and n=120 respectively) rather than true absence of effect. The ethnic-specific allele frequency differences — the T (risk) allele is most common in East Asians, less frequent in Africans — also complicate cross-ethnic replication.

Practical Actions

rs10033900 acts as a lifetime background modifier of retinal complement control. The variant itself doesn't cause AMD — many TT homozygotes will never develop it — but it shifts the odds, particularly when combined with other AMD risk factors like smoking, obesity, CFH Y402H¹³¹³ CFH Y402H
The complement factor H variant at rs1061170, sun exposure, and diet.

For people carrying one or two T alleles, two evidence-based strategies deserve particular attention. First, diet: high dietary lutein and zeaxanthin¹⁴¹⁴ lutein and zeaxanthin
Carotenoids that accumulate in the macula, filtering high-energy blue light and providing local antioxidant protection consumption is specifically associated with reduced AMD risk in genetically susceptible individuals. The AREDS2 trial established that supplementation with lutein (10 mg) and zeaxanthin (2 mg) daily reduces progression to advanced AMD by 10–25%. Second, complement-targeted therapies for geographic atrophy AMD (pegcetacoplan and avacincaptad pegol, both FDA-approved since 2023) represent a direct mechanistic intervention for those who develop advanced disease — people with complement-pathway variants may have the most to gain from these therapies.

Smokers with T alleles carry compounded risk: smoking independently activates complement, directly amplifying the same pathway that CFI rs10033900 impairs regulation of.

Interactions

rs10033900 interacts within the complement pathway with CFH rs1061170 (Y402H)¹⁵¹⁵ CFH rs1061170 (Y402H)
The strongest AMD risk variant, disrupting CFH binding to glycosaminoglycans on Bruch's membrane. Multiple large AMD studies have shown that complement pathway risk variants act additively to near-multiplicatively: individuals carrying risk alleles at both CFH Y402H and CFI rs10033900 have substantially greater AMD risk than either variant alone would predict. Epidemiological data from AMD genetics consortia suggest individuals with high-risk complement haplotypes spanning CFH, CFI, and CFB/C2 show odds ratios exceeding 10-fold for advanced AMD compared to those with all protective alleles.

The ARMS2/HTRA1 locus at chromosome 10q26 (rs10490924) contributes independent non-complement risk for AMD, particularly neovascular AMD. The interaction between complement pathway variants (CFH, CFI) and ARMS2 risk alleles likely explains much of the population-attributable risk for advanced AMD.